Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Treasury Shares (2020 - 2025)

KalVista Pharmaceuticals' Treasury Shares history spans 4 years, with the latest figure at $177500.0 for Q2 2025.

  • On a quarterly basis, Treasury Shares fell 71.66% to $177500.0 in Q2 2025 year-over-year; TTM through Apr 2025 was $177500.0, a 71.66% decrease, with the full-year FY2025 number at $177500.0, down 71.66% from a year prior.
  • Treasury Shares hit $177500.0 in Q2 2025 for KalVista Pharmaceuticals, down from $626272.0 in the prior quarter.
  • Over the last five years, Treasury Shares for KALV hit a ceiling of $742242.0 in Q2 2023 and a floor of $177500.0 in Q2 2025.
  • Historically, Treasury Shares has averaged $515338.0 across 3 years, with a median of $626272.0 in 2024.
  • Biggest five-year swings in Treasury Shares: decreased 15.62% in 2024 and later plummeted 71.66% in 2025.
  • Tracing KALV's Treasury Shares over 3 years: stood at $742242.0 in 2023, then dropped by 15.62% to $626272.0 in 2024, then tumbled by 71.66% to $177500.0 in 2025.
  • Business Quant data shows Treasury Shares for KALV at $177500.0 in Q2 2025, $626272.0 in Q2 2024, and $742242.0 in Q2 2023.